Published: 10:55 27.06.2003 GMT+2 /HUGIN /Source: Genmab A/S /CSE:
GENM /ISIN: DK0010272202
Genmab Files CTA for HuMax-EGFr to Treat Cancer
Genmab files Clinical Trial Application (CTA) to start open label
Phase I/II clinical trial using HuMax-EGFr to treat head and neck
cancer
http://reports.huginonline.com/909402/119881.pdf
For further information please contact Rachel Gravesen:
rcg@genmab.com or +45 3344 7734
This press release was brought to you by Hugin Online, distributor of
electronic press releases for companies listed on selected European
stock exchanges. Address:
http://www.huginonline.com/Denmark/GENM
To alter your subscription profile or to unsubscribe, please go to:
http://www.huginonline.com/email
The Hugin Team